Critical evaluation of hormonal therapy for carcinoma of the prostate

被引：80

作者：

Chodak, GW

Keane, T

Klotz, L

Hormone Therapy Study Grp

机构：

[1] Midwest Prostate & Urol Hlth Ctr, Chicago, IL 60640 USA

[2] Emory Univ, Atlanta, GA 30322 USA

[3] Univ Toronto, Toronto, ON, Canada

来源：

关键词：

D O I：

10.1016/S0090-4295(02)01677-1

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：201 / 208

页数：8

共 57 条

[1] Adib RS, 1997, BRIT J UROL, V79, P235
[2] [Anonymous], 1995, Lancet, V346, P265
[3] BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO
[4] 2-9
[5] Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma
Bazinet, M
Zheng, W
Begin, LR
Aprikian, AG
Karakiewicz, PI
Elhilali, MM
[J]. UROLOGY, 1997, 49 (05) : 721 - 725
[6] Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
Bolla, M
Gonzalez, D
Warde, P
Dubois, JB
Mirimanoff, RO
Storme, G
Bernier, J
Kuten, A
Sternberg, C
Gil, T
Collette, L
Pierart, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) : 295 - 300
[7] Bolla M., 1999, International Journal of Radiation Oncology Biology Physics, V45, P147, DOI 10.1016/S0360-3016(99)90023-8
[8] Byar D P, 1988, NCI Monogr, P165
[9] BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO
[10] 2-C